- Posted
- Categories
-
- OpenPrescribing
New anticoagulation measure launched in OpenPrescribing Hospitals
New oral anticoagulants measure has launched in OpenPrescribing Hospitals.
OpenPrescribing is our most widely used applied data science project, with 20,000 unique users every month. It lets any interested user explore NHS GP prescribing behaviour across the whole country, down to the level of individual doses and brands, of individual drugs, at individual practices, each month. We have a range of prespecified measures showing opportunities to improve the quality, safety, and cost effectiveness of prescribing. We also let users devise their own analyses and alerts. OpenPrescribing represents a huge amount of complex data science “under the bonnet”, with papers on our innovative methods published in BMJ and elsewhere. We have also generated a large body of research on trends and variation in clinicians’ choice of treatments, and what drives change in clinical practice, including randomised trials on our own interventions. Alongside this we have generated extensive technical and policy insights on how data can be put to good use in the NHS, where the blockers lie, and how they can be overcome.
A descriptive observational study of CDK4/6 inhibitor (palbociclib, ribociclib, and abemaciclib) uptake and dose reduction in NHS trusts in England, using OpenPrescribing Hospitals
Status: Preprint
This study explored trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS Trusts in England.
Status: Published
A description of the OpenPrescribing Hospitals platform.
Status: Preprint
By applying one of our existing analysis tools to a national dataset, we were able to rank NHS organisations by reduction in opioid prescribing rates. Highly ranked organisations are candidates for further qualitative research into intervention design and implementation.
Status: Published
New oral anticoagulants measure has launched in OpenPrescribing Hospitals.
Najma Moallin reflects on working with real-world data, navigating uncertainty, and developing as a researcher.
Five new low value prescribing measures have been launched.
We’ve launched a new AIR/MART inhaler measure to monitor the impact of the changes introduced in the BTS/NICE/SIGN asthma guideline.